A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Sunitinib (Primary) ; Capecitabine; Docetaxel; Gemcitabine; Paclitaxel; Vinorelbine; Vinorelbine
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Aug 2011 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.
- 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.